Table 2 Top 15 differentially expressed metabolites in HAPH patients compared to healthy controls.

From: Integrative proteomics and metabolomics reveal important pathways and potential biomarkers in high-altitude pulmonary hypertension

Metabolites

LOG₂ FC

FC

P-adjust

Pantothenol ↑

1.386

2.613

0.182

2-(2-Methylpropoxy) naphthalene ↑

1.144

2.211

0.200

Plastoquinone 3 ↓

−0.904

0.534

0.182

2’-O-Methylcajanone ↓

−0.741

0.598

0.012

Rhizonin A ↓

−0.677

0.625

0.182

(Z, Z)−2,9,16-Heptadecatriene-4,6-diyn-8-ol ↓

−0.583

0.668

0.092

2-O-(5,8,11,14,17-Eicosapentaenoyl)−1-O-hexadecylglycero-3-phosphocholine ↑

0.534

1.447

0.182

PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z)) ↑

0.523

1.437

0.047

Estrone ↓

−0.522

0.697

0.118

Butyl 2-aminobenzoate ↓

−0.516

0.699

0.146

PC(P-18:1(9Z)/16:0) ↑

0.498

1.412

0.047

PC(22:1(13Z)/14:0) ↑

0.481

1.396

0.146

Ascochitine ↓

−0.476

0.719

0.182

Octadecylamine ↑

0.466

1.381

0.047

L-Hexahydro-3-imino-1,2,4-oxadiazepine-3-carboxylic acid ↓

−0.463

0.726

0.092

  1. FC: Fold change (treatment/control). LOG₂ FC: Log2-transformed fold change values. Positive values indicate up-regulation in treatment group; negative values indicate down-regulation. P-adjust: Benjamini-Hochberg] for multiple testing. Abbreviations: HAPH, high-altitude pulmonary hypertension.
Back to article page